Modified Vero cell induced by Bifidobacterium bifidum inhibits enterohemorrhagic Escherichia coli O157:H7 cytopathic effect

• Main Authors: Tahamtan, Y., Namdari, N., Kargar, M.
• Format: Article
• Language: English
• Published: Razi Vaccine and Serum Research Institute 2014-11-01
• Series: Archives of Razi Institute
• Subjects: E. coli O157:H7; B. bifidum; Vero cell
• Online Access: http://www.archrazi.com/browse.php?a_id=509&sid=1&slc_lang=en
• ISSN: 0365-3439; 2008-9872

Enterohemorrhagic Escherichia coli (EHEC), such as E. coli O157:H7, are emerging food-borne pathogens worldwide. This micro-organism can damage the epithelial tissue of the large intestine. The cytotoxic effects can be neutralized by probiotics such as Bifidobacterium bifidum. Probiotics are viable cells that have beneficial effects on the health of the host. The preventing activity of B. bifidum against E. coli O157 was studied using a Vero cell model. Vero cell was pretreated with viable B. bifidum and incubated for either 3 h to 24 h and then collected from the cell to make modified Vero cell (MVC). Indirect antibacterial effects of B. bifidum were demonstrated by reduction of attachment of E. coli O157:H7 to MVC. The maximum reduction was resulted in pretreatment of Vero cell with B. bifidum for 24 h before infection. B. bifidum attenuated E. coli O157:H7 attachment to MVC up to 10 days of incubation. To our knowledge, MCV prevented Vero cell line injury induced by E. coli O157:H7. Therefore, B. bifidum can be used for inhibition of E. coli O157:H7 cytopathic effect (CPE) in Vero cell model, even as pretreatment of the cell line.